Report from Annual General Meeting of Vitrolife AB
At Vitrolife’s Annual General Meeting yesterday, April 27, the following, amongst other things, was decided:
- The Board’s proposed dividend of SEK 0.60 for the financial year 2010 was approved. May 2, 2011 was adopted as the record day.
- Changes of the Articles of Association entailing, among other things, auditors mandate period to be three years, and notice of a General Meeting of shareholders shall be given to shareholders through an announcement in the Swedish Official Gazette (Post- och Inrikes Tidningar) and on the company’s website. That notice has been given shall be announced in Dagens Industri.
- Re-election of Board members Patrik Tigerschiöld, Fredrik Mattsson, Madeleine Olsson-Eriksson, Tord Lendau, Maris Hartmanis and Barbro Fridén, in accordance with the election committee’s proposal. Patrik Tigerschiöld was re-elected Chairman of the Board.
- Re-election of Öhrlings PricewaterhouseCoopers, with the authorized accountant Birgitta Granquist as head auditor, as auditor for a period of three years.
- An increase of the remuneration to the members of the Board totalling SEK 770,000 (700,000), of which SEK 220,000 (200,000) is allocated to the Chairman of the Board and SEK 110,000 (100,000) to each of the other Board members. Fees to the auditor shall be paid in accordance with reasonable invoicing.
- Authorization for the Board, for the time up until the next Annual General Meeting and on one or more occasions, to take a decision on the issue of a maximum of 1,950,000 shares in total, corresponding to approximately 10 percent of the company’s share capital.
- The Board was authorized to take a decision, up until the next Annual General Meeting and on one or more occasions, with regard to the acquisition and transfer of the company’s own shares, at the most 10 percent of the company’s shares.
- The proposed principles for remuneration and other conditions of employment for the senior management were approved.
Gothenburg, April 28, 2011
VITROLIFE AB (Publ)
Queries should be addressed to:
Magnus Nilsson, CEO, phone +46 31 721 80 61
Anne-Lie Sveder, CFO, phone +46 31 721 80 13
Vitrolife is a global biotechnology/medical device Group that works with developing, manufacturing and selling advanced products and systems for the preparation, cultivation and storage of human cells, tissue and organs. The company has business activities within three product areas: Fertility, Transplantation and Stem Cell Cultivation. The Fertility product area works with nutrient solutions (media), cryopreservation products and advanced consumable instruments such as needles and pipettes, for the treatment of human infertility. The Transplantation product area works with solutions and systems to evaluate and maintain organs outside the body in order to select usable organs and keep them in optimal condition while waiting for transplantation. The Stem Cell Cultivation product area works with media and instruments to enable the use and handling of stem cells for therapeutic purposes.
Vitrolife today has approximately 220 employees and its products are sold in more than 85 markets. The company is headquartered in Gothenburg, Sweden, and there are subsidiaries in USA, Australia, France, Italy, United Kingdom and Japan. Production facilities are located in Sweden and the USA. The Vitrolife share is listed on NASDAQ OMX Stockholm, Small Cap.
Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity number 556354-3452.
Tel: +46 31 721 80 00. Fax: +46 31 721 80 90. E-mail: email@example.com. Website: www.vitrolife.com.
Vitrolife is required to publish the information in this press release in accordance with the Swedish Securities Market Act. The information was submitted for publication on Thursday April 28, 2011, at 8.30 a.m. CET.
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.